The role of taxanes in HR+ve/HER2-ve metastatic breast cancer (MBC) patients (pts) from adjuvant to metastatic setting in the clinical practice: Results from GIM13-AMBRA study.
Giorgio Mustacchi(University of Trieste), Ornella Garrone(Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo), Filippo Montemurro(Roche (Switzerland)), Vincenzo Graziano(University of Chieti-Pescara), P. Pronzato(Accademia Nazionale dei Lincei), Claudia De Angelis(University of Naples Federico II), Marina Elena Cazzaniga(Azienda Ospedaliera San Gerardo), Paolo Marchetti(Istituto Dermopatico dell'Immacolata), Alessandra Beano(Presidio Ospedaliero), Lorenzo Livi(European Society for Sexual Medicine), Laura Biganzoli(Hospital of Prato), Anna Turletti(Ospedale Martini), Lucia Del Mastro(Ospedale Policlinico San Martino), Sabino De Placido, Ferdinando Riccardi(Ospedale Antonio Cardarelli), Emanuela Romagnoli(Medica (Italy))
Cited by 1
Related Papers
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
|Annals of Oncology|2020|1.4k
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
|Annals of Oncology|2018|1.2k